Natürliche und synthetische Glykosaminoglykane. Molekulare Charakteristika als Grundlage unterschiedlicher Arzneistoffprofile.
Hämostaseologie 28, 51–61
Alban, S. (2010)
Heparine und andere Glykoantikoagulatien.
in: B. Pötzsch u. K. Madlener (hrsg.): Hämostaseologie Springer-Verlag Berlin Heidelberg, 2. Auflage, S. 750–778
Alwood A. J., A. B. Downend, K. A. Slensky, J. A. Fox, S. A. Simpson, S. M.
Donahue, L. S. Waddell, C. M. Otto (2004)
Evaluation of thromboelastography (TEG) in normal cats.
Abstracts from the 10th international veterinary emergency and critical care symposi-um september 8–12, 2004. San Diego, California
J. Vet. Emerg. Crit. Care 14, S1 (abstract)
Alwood, A. J., A. B. Downend, B. M. Brooks, K. A. Slensky, J. A. Fox, S. A.
Simpson, L. S. Waddell, J. E. Baumgardner, C. M. Otto (2004) Anticoagulant effects of low-molecular-weight heparins in healthy cats.
J. Vet. Intern. Med. 21, 378–387
Alwood, A. J., A. B. Downend, M. B. Brooks, K. A. Slensky, J. A. Fox, S. A.
Simpson, L. S. Waddell, J. E. Baumgardner, C. M. Otto (2007) Anticoagulant effects of low-molecular-weight heparins in healthy cats.
J. Vet. Intern. Med. 21, 378–387
Artang, R., N. J. Frandsen, J. D. Nielsen (2009)
Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study.
Thromb. J. 10, 7–14
Baker, B. A., M. D. Adelman, P. A. Smith, J. C. Osborn (1997)
Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
Arch. Intern. Med. 157, 2475–2479
Barnerjee, A., S. L. Blois, R. D. Wood (2011)
Comparing citrated native, kaolin-activated, and tissue factor-activated samples and determing intraindividual variability for feline thromboelastography.
J. Vet. Diagn. Invest. 23, 1109–1113
Basu, D., A. Gallus, J. Hirsh, J. Cade (1972)
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.
N. Engl. J. Med. 287, 324–327
Bates, S. M., J. I. Weitz, M. Johnston, J. Hirsh, J. S. Ginsberg (2001)
Use of a fixed activated partial Thromboplastin time ratio to establish a therapeutic range for unfractionated heparin.
Arch. Intern. Med. 161, 385–391
Baty, C. J. (2001)
Aortic thromboembolism.
In: August, J.R., (Hrsg.) Consultations in feline internal medicine. Philadelphia, PA:
WB Saunders, 299–306
Bauer, N., O. Eralp, A. Moritz (2009)
Establishment of reference intervals for kaolin-activated thromboelastography in dogs including an assessment of the effects of sex and anticoagulant use.
J. Vet. Diagn. Invest. 21, 641–648
Bjornsson, T. D. u. P. V. Nash (1986)
Variability in heparin sensitivity of APPT reagents.
Am. J. Clin. Pathol. 86, 199–204
Bjørnvad, C. R., B. Wiinberg, A. L. Jensen, A. T. Kristensen (2008)
Evaluation of tissue factor and kaolin activated thromboelastography on feline citrat-ed whole blood from clinically healthy cats.
J. Vet. Intern. Med. 22, s 739 (abstract)
Blajchman, M. A., E. Young, F. A. Ofosu (1989)
Effects of unfractionated heparin, dermatan sulphate and low molecular weight hep-arin on vessel wall permeability in rabbits.
Ann. N. Y. Acad. Sci. 556, 245–254
Borgarelli, M., L. Venco, P. M. Piga, F. Bonino, W. G. Ryan (1997) Surgical removal of heartworms from the right atrium of a cat.
J. Am. Vet. Med. Assoc. 211, 68–69
Bounameaux, H., G. A. Marbet, B. Lämmle, R. Eichlisberger, F. Duckert (1980) Monitoring of heprin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis oft he behavior of antithrombin III.
Am. J. Clin. Pathol. 74, 68–73
Brill-Edwards, P., J. S. Ginsberg, M. Johnston, J. Hirsh (1993) Establishing a therapeutic range for heparin therapy.
Ann. Intern. Med. 119, 104–109
Calatzis, An., P. Fritzsche, A. I. Calatzis, A. Stemberger (1995)
roTEG Coagulation Analyzer - a new approach to whole blood coagulation analysis Ann. Haematol. 170, P263
Calatzis, An., A. L. Calatzis, P. Fritzsche, M. Kling, R. Hipp, A. Stemberger (1996)
An analysis of the correlation of the roTEG coagulation analyser and the Hellige thrombelastograph D.
Ann. Hematol. 72, P87 (Abstract)
Calatzis, An., P. Fritzsche, A. L. Calatzis, M. Kling, R. Hipp, A. Stemberger (1996)
A comparison of the technical principle of the roTEG coagulation analyser and con-ventional thrombelastographic systems.
Ann. Hematol. 72, P90
Cammerer, U., W. Dietrich, T. Rampf, S. L. Braun, J. A. Richter (2003)
The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery.
Anesth. Analog. 96, 51–57
Campbell, N. R., R. D. Hull, R. Brant, D. B. Hogan, G. F. Pineo, G. E. Raskob (1996)
Aging and heparin-related bleeding.
Arch. Intern. Med. 22, 857–860
Chiu, H. M., J. Hirsh, W. L. Yung, E. Regoeczi, M. Gent (1977)
Relationship between the anticoagulant and antithrombotic effects of heparin in ex-perimental venous thrombosis.
Blood 49, 171–184
Coon, W. W. u. P. W. Willis (1974)
Hemorrhagic complications of anticoagulant therapy.
Arch. Intern. Med. 133, 386–392
Coppell, J. A., U. Thalheimer, A. Zambruni, C. K. Triantos, A. F. Riddel, A. K.
Burroughs, D. J. Perry (2006)
The effects of unfractionated heparin, low molecular weight heparin and dranapoid on the thromboelastogram (TEG): an in-vitro comparison of standard and hepa-rinase-modified TEGs with conventional coagulation assays.
Blood Coagul. Fibrinolysis 17, 97–104
Crowther, M. A. u. T. E. Warketin (2008)
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents.
Blood 111, 4871–4879
Cucker A., B. Ptashkin, B. A. Konkle, S. W. Pipe, H. C. Whinna, X. L. Zheng, D.
B. Cines, E. S. Pollak (2008)
Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
J. Thromb. Haemost. 7, 80–86
Davidson, B. L., E. A. Rozanski, A. S. Tidwell, A. M. Hoffman (2006) Pulmonary thromboembolism in a heartworm-positive cat.
J. Vet. Intern. Med. 20, 1037–1041
Diquéloue, A., C. Barbaste, A. M. Gabaig, C. Trumel, N. Abella-Bourges, J-F.
Guelfi, A. Bousquet Mélou (2005)
Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs.
Vet. Clin. Pathol. 34, 237–242
Donahue, S. M. u. C. M. Otto (2005)
Thromboelastography: a toll for measuring hypercoagulability, hypocoagulability, and fibrinolysis.
J. Vet. Emerg. Crit. Care 15, 9–16
Eikelboom, J. W. u. J. Hirsh (2006)
Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb.
Haemost. 96, 547–552
Estrin, M. A., C. E. Wehausen, C. R. Jessen, J. A. Lee (2006) Disseminated intravascular coagulation in cats.
J. Vet. Inter. Med. 20, 1334–1339
Fenty, R. K., A. M. deLaforcade, S. P. Shaw, T. E. O´Toole (2011)
Identification of hypercoagulability in dogs with primary immune-mediated hemolytic anemia by means of thromboelastography.
J. Am. Vet. Med. Assoc. 238, 463–467
Fernandez, F., P. N´guyen, J. van Ryn, F. A. Ofosu, J. Hirsh, M. R. Buchanan (1986)
Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet de-fect.
Thromb. Res. 43, 491–495
Fox, P. R (1999)
Textbook of canine and feline cardiology: principles and clinical practice.
P. R. Fox, D. Sisson u. N. S. Moise (Hrsg.) 2. Auflage, Verlag Saunders, Philadelphia, S. 62
Francis, J. L., D. A. Francis, G. J. Gunathilagan (1994)
Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyz-er and thromboelastography.
Thromb Res. 74, 335–46.
Ganther, M. T. u. C. K. Hofer (2008)
Coagulation monitoring: current techniques and clinical use of viscoelastic point-of.care caogulation devices.
Anesth. Analg. 106, 1366–1375
Glazier, R. L. u. E. B. Crowel (1976)
Randomized prospective trial of continuous vs intermittent heparin therapy.
JAMA 236, 1365–1367
Goggs, R., L. Benigni, V. L. Fuentes, D. L. Chan (2009) Pulmonary thromboembolism.
J. Vet. Ermerg. Crit. Care. 19, 30–52
Greene, C. E. u. E.Meriwether (1982)
Activated partial thromboplstin time and activated coagulation time in monitoring heparinised cats.
Am. J. Vet. Res. 43, 1473–1477
Haliassos A., H. Melita-Manolis, D. Aggelaki, D. Tassi, G. Terzoglou (1997)
Use of anti-Xa activity as a marker for heparin-induced bleeding in patients with APTT>180 s.
Clin. Chem. 43, 1781–1782
Hall, D. J., J. E. Rush, A. M. deLaforcade, S. P. Shaw (2012)
Kaolin-activated thromboelastography in echocardiographically normal cats.
Am. J. Vet. Res. 73, 775–778
Handeland, G. F., U. Abildgaard, H. A. Holm, K. E. Arnesen (1990)
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of un-fractionated and low molecular weight heparin.
Eur. J. Clin. Pharmacol. 39, 107–112
Harnett, B. E. u. M. E. Kerl (2007)
Unfractionated and low-molecular-weight heparin for hypercoagulability in dogs and cats.
Vet. Med. März, 187–202
Hartert, H. (1948)
Blutgerinnungsstudien mit der Thromboelastographie, einem neuen Untersuchungs-verfahren.
Klin. Wochenschr. 26, 577–583
Helmond, S. E., D. J. Polzin, P. J. Armstrong, M. Finke, S. A. Smith (2010)
Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs.
J. Vet. Intern. Med. 24, 597–605
Hirsh, J. u. R. Raschke (2004)
Heparin and Low-molecular-weight Heparin: The seventh ACCP conference on an-tithrombotic and thrombolytic therapy.
Chest 126, Suppl, 188S–203S
Hirsh, J., K. A. Bauer, M. B. Donati, M. Gould, M. M. Samana, J. I. Weitz (2008) Parenteral anticoagulants: American college of chest physicans evidence based cin-ical practice guidelines (8th edition).
Chest 133, 141S–159S
Hirsh, J., T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R.
Raschke, C. Granger, E. M. Ohman, J. E. Dalen (2001)
Heparin and low-molecular weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
Chest 119, 64S–94S
Hoffmann, R. (1973)
Verbrauchskoagulopathie bei spontaner Panleukopenie der Haus- und Wildkatzen.
Berl. Münch. Tierärztl. Wochenschr. 4, 72–73
Hull, R. D., G. E. Raskob, D. Rosenbloom, A. A. Panju, P. Brill-Edwards, J. S.
Ginsberg, J. Hirsh, G. J. Martin, D. Green (1990)
Heparin for 5 days as compared with 10 days in the initial treatment of proximal ve-nous thrombosis.
N. Engl. J. Med. 322, 1260–1264
Hyers, T. M., R. D. Hull, J. G. Weg (1995)
Antithrombotic therapy for venous thromboembolic disease.
Chest 108, 335S–351S
Jessen, L. R., B. Wiinberg, A. L. Jensen, M. Kjelgaard-Hansen, K. H. Jensen, L.
B. Pedersen (2008)
In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clot-ting time.
Vet. Clin. Pathol. 37, 363–372
Kang, Y. G., D. J. Martin, J. Marquez, J. H. Lewis, F. A. Bontempo, B. W. Shaw, T. E. Starzl, P. M. Winter (1985)
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation.
Anesth. Analg. 64, 888–896
Kernohan, R. J. (1966)
Heparin therapy in thromboembolic disease.
Lancet. 19, 621–623
Kitchen, D. P., S. Kitchen, I. Jennings, T. Woods, I. Wolker (2010)
Quality assurance and quality control of thrombelastography and rotational thrombo-elastometry: the UK NEQAS for blood coagulation experience.
Semin. Thromb. Hemost. 36, 757–763
Kitchen, S. (2000)
Problems in laboratory monitoring of heparin dosage.
Br. J. Haematol. 111, 397–406
Kitchen, S. u. F. E. Preston (1996)
The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
Thromb. Haemost. 75, 734–739
Kitchen, S., I. Jennings, T. A. L. Woods, F. E. Preston (1996)
Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.
J. Clin. Pathol. 49, 10–14
Kjelgaard-Hansen, M. u. A. Lundorff Jensen (2010)
Reference intervals in D. J. Weiss u. K. J. Wardrop (Hrsg.): Schalm´s Veterinary Hematology
Wiley-Blackwell 6. Auflage, 1034–1038
Klein, S. M., T. F. Slaughter, P. T. Vail, B. Ginsberg, H. E. El-Moalem, R. Ale-xander, F. D´Ercole, R. A. Greengrass, T. T. M. Perumal, I. Welsby, T. J. Gan (2000)
Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations.
Anesth. Analg. 91, 1091–1095
Kol, A., D. L. Borjesson (2010)
Application of thrombelatography / thromboelastometry to veterinary medicine.
Vet. Clin. Pathol. 39, 405–416
Kraft, W. (1973)
Das Thrombelastogramm der gesunden Hauskatze und die Behandlung der Ver-brauchskoagulopathie bei Panleukopenie.
Berl. Münch. Tierärztl. Wochenschr. 86, 394–396
Kristensen, A. T., B. Wiinberg, L. R. Jessen, E. Andreasen, A. L. Jensen (2008) Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia.
J. Vet. Intern. Med. 22, 140–147
Landefeld, C. S., E. F. Cook, M. Flatley, M. Weisberg, L. Goldman (1987)
Identification and preliminary validation of predictors of major bleeding in hospita-lized patients starting anticoagulant therapy.
Am. J. Med. 82, 703–713
Lang, T. u. M. von Depka (2006)
Diagnostische Möglichkeiten und Grenzen der Thromboelastometrie/-graphie.
Hämostaseologie 26, 20–29
Lang, T., A. Bauters, S. L. Braun, B. Pötzsch, K.-W. von Pape, H.-J. Kolde, M.
Lakner (2005)
Multi-centre investigation on reference ranges for ROTEM thromboelastometry.
Blood Coagul. Fibrinol. 16, 301–310
Lee, B.Y., S. Taha, F. S. Trainor, D. Kavner, W. J. McCann (1980)
Monitoring heparin therapy with thromboelastography and activated partial thgrom-boplastin time.
World J. Surg. 4, 323–330
Lehman, C. M. u. E. L. Frank (2009)
Laboratory monitoring of heparin therapy: partial thromboplastin time or Anti-Xa as-say?
Lab. Med. 40, 47–51
Levine, M. H., J. Hirsh, M. Gent, A. G. Turpie, M. Cruickshank, J. Weitz, D. An-derson, M. Johnson (1994)
A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Arch. Intern. Med. 154, 49–56
Levine, M. N., G. Raskob, J. Hirsh (1989)
Hemorrhagic complications of long-term anticoagulant therapy.
Chest 95, 26S–36S
Levine, M. N., G. Raskob, R. J. Beyth, C. Kearon, S. Schulman (2004)
Hemorrhagic complications of anticoagulant treatment. The seventh ACCP confer-ence on antithrombotic and thrombolytic therapy.
Chest 126, 287S–310S
Luddington, R. J. (2005)
Thrombelastography / thromboelastometry.
Clin. Lab. Haem. 27, 81–90
Lunsford, K. V. u. A. J. Mackin (2007)
Thromboembolic therapies in dogs and cats: an evidence-based approach.
Vet. Clin. Small Anim. 37, 579–609
Mahla, E., T. Lang, M. N. Vicenzi, G. Werkgartner, R. Maier, C. Probst, H. Metz-ler (2001)
Thromboelastography for monitoring prolonged hypercoagulability after major ab-dominal surgery.
Anesth. Analg. 92, 572–7.
Mallet, S. V. u. D. J. A. Cox (1992) Thrombelastography.
Br. J. Anaesth. 69, 307–313
Mant, M. J., B. D. O´Brien, K. L. Thong, G. W. Hammond, R. V. Birtwhistle, M. G.
Grace (1977)
Haemorrhagic complications of heparin therapy.
Lancet 28, 1133–1135
Marschner, C. B., C. B. Bjørnvad, A. T. Kristensen, B. Wiinberg (2010)
Thromboelastography results on citrated whole blood from clinically healthy cats de-pend on modes of activation.
Acta. Vet. Scand 52, 38–42 McLean, J. (1916)
The thromboplastic action of cephalin.
Am. J. Physiol. 41, 250–257
McMichael, M. A. u. S. A. Smith (2011)
Viscoelastic coagulation testing: technology, applications, and limitations.
Vet. Clin. Pathol. 40, 140–153
Mischke, R., A. Deniz, I. Nolte (1994)
[Optimized methods for measuring coagulation factors II, IV, VII and X in cats]
Dtsch. Tierärtzl. Wochenschr. 101, 430–433
Mischke, R. (2003)
Heparin in vitro sensitivity oft he activated partial thromboplastin time in canine plasma depends on reagent.
J. Vet. Diagn. Invest. 15, 588–591
Mischke, R. H., C. Schüttert, S. I. Grebe (2001)
Anticoagulant effects of repeated subcutaneous injections of high doses of unfrac-tionated heparin in healthy dogs.
Am. J. Vet. Res. 62, 1887–1891
Mischke, R. u. C. Jacobs (2001)
The monitoring of heparin administration by screening tests in experimental dogs.
Res. Vet. Science 70, 101–108
Mischke, R., A. Deniz, I. Nolte (1996)
Influence of sample predilution on the sensitivity of prothrombin time in feline plas-ma.
Zentralbl. Veterinarmed. A. 43, 155–162
Mischke, R., C. Schüttert, S. I. Grebe (2001)
Anticoagulant effects of repeated subcutaneous injections of high doses of unfrac-tionated heparin in healthy dogs.
Am. J. Vet. Res. 62, 1887–1891
Moldal, E. R., A. T. Kristensen, M. E. Peeters, A. Nødtvedt, J. Kirpensteijn (2012)
Hemostatic response to surgical neutering via ovariectomy and ovariohysterectomy in dogs.
Am. J. Vet. Res. 73, 1469–1476
Moldal, E. R., J. Kirpensteijn, A. T. Kristensen, H. A. Haga, A. Nødtvedt, T. Erik-sen (2012)
Evaluation of inflammatory and hemostatic surgical stress responses in male cats after castration under general anesthesia with or without local anesthesia.
Am. J. Vet. Res. 73, 1824–1831
Montgomery, A., C. G. Couto, K. Schober, P. Vilar Saavedra, N. Westendorf, M.
C. Iazbik (2008)
Thromboelastography in healthy cats.
J. Vet. Intern. Med. 22, 774 (abstract)
Moore, K. E., N. Morris, N. Dhupa, R. J. Murtaugh, J. E. Rush (2000)
Retrospective study of streptokinase administration in 46 cats with arterial thrombo-embolism.
J. Vet. Ermerg. Crit. Care. 10, 245–257
Morabia, A. (1986)
Heparin doses and major bleedings.
Lancet 1, 1278–1279.
Nielsen, L. N., B. Wiinberg, M. Kjelgaard-Hansen, A. Lundorf Jensen, A. T. Kris-tensen (2011)
Prolonged activated prothromboplastin time and breed specific variation in haemo-static analytes in healthy Bernese Mountain dogs.
Vet. J. 190, 150–153
Nielsen, V. G. (2002)
The detection of changes in heparin activity in the rabbit: a comparison of anti-Xa activity, thrombelastography®, activated partial thromboplastin time, and activated coagulation time.
Anesth. Analg. 95, 1503–1506
Nielsen, V. G. u. B. T. Geary (2000)
Hepatoenteric ischemia-reperfusion increases circulation heparinoid activity in rab-bits.
J. Crit. Care 15, 142–146
Nielsen, V.G. (2007)
A comparison of the thrombelastograph and the ROTEM.
Blood Coagul. Fibrinolysis 18, 247–252
Nieuwenhuis H. K., J. Albada, J. D. Banga, J. J. Sixma (1991)
Identification of risk factors for bleeding during treatment of acute venous thrombo-embolism with heparin or low molecular weight heparin.
Blood 78, 2337–2343
Olson, J. D., C. F. Arkin, J. T. Brandt, M. T. Cunningham, A. Giles, J. A. Koepke, D. L. Witte (1998)
College of American Pathologists Conference XXXI on laboratory monitoring of anti-coagulant therapy: Laboratory monitoring of unfractionated heparin therapy.
Arch. Pathol. Lab. Med. 122, 782–798
Otto, C.M., T. M. Rieser, M. B. Brooks, M. W. Russel (2000) Evidence of hypercoagulability in dogs with parvoviral enteritis.
J. AM. Vet. Assoc. 217, 1500–1504
Paltrinieri, S., C. Meazza, A. Giordano, C. Tunesi (2008) Validation of thromboelastometry in horses.
Vet. Clin. Pathol. 37, 277–285
Pause, B. (1988)
Vergleichende Untersuchung zur Gerinnungsdiagnostik mit dem Resonanzthrombo-graphen und dem ThrombelastoResonanzthrombo-graphen gemessen an der Thrombozytenzahl, dem Fibrinogengehalt, der Prothrombinzeit und der aktivierten partiellen Thromboplastin-zeit bei klinisch gesunden und kranken Hunden, Katzen und Pferden.
Inaugural-Dissertation Justus-Liebig-Universität Gießen SS 1988
Pittman, J. R., A. Koenig, B. M. Brainard (2010)
The effect of unfractionated heparin on thrombelastographic analysis in healthy dogs.
J. Vet. Emerg. Crit. Care 20, 216–223
Pouchelon J. L., V. Chetboul, P. Devauchelle, F. Delisle (1997)
Diagnosis of pulmonary thromboembolism in a cat using echocardiography and pul-monary scintigraphy.
J. Small Anim. Pract. 38, 306–310
Raschke, R., J. Hirsh, J. R. Guidry (2003)
Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin.
Ann. Intern. Med. 138, 720–723
Ray, M. J., E. J. Perrin, I. R.smith, G. A. T. Hawson (1996)
A proposed model to monitor heparin therapy using the concentrated thrombin time which allows standardisation of reagents and improved estimation of heparin con-centrations.
Blood Coagul. Fibrinolysis 7, 515–521
Rivera Ramirez, P.A., A. Deniz, W. Wirth, R. Mischke (1997)
Antithrombin III activity in health cats and its changes in selected disease.
Berl. Münch. Tierärztl. Wochenschr. 110, 440–444
Roche, A.M., M. F. James, M. P. Grocott, M. G. Mythen (2006)
Just scratching the surface: varied coagulation effects of polymer containers on TEG variables.
Eur. J. Anaesthesiol. 23, 45–49
Rogers, C. L., T. E. O´Toole, J. H. Keating, D. G. Penninck, C. R. L. Webster (2008)
Portal vein thrombosis in cats: 6 cases (2001–2006).
J. Vet. Intern. Med. 22, 282–287
Rosborough T. K. (1999)
Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time.
Pharmacotherapy 19, 760–766
Rosenberg, A. F., M. Zumberg, L.Taylor, A. LeClaire, N.Harris (2010)
The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
J. Pharm. Pract. 23, 210–216
Roullet, S., J. Pillot, G. Fryburger, M. Biasis, A. Quinart, A. Rault, P. Revel, F.
Sztark (2010)
Rotation thromboelastometry detects thrombocytopenia and hyperfibrinogenaemia during orthotopic liver transplantation.
Br. J. Anaesth. 104, 422–428
Rugeri, L., A. Levrat, J. S. David, E. Delecroix, B. Floccard, A. Gros, B. Al-laouchiche, C. Negrier (2007)
Diagnosis of early coagulation abnormalities in trauma patients by rotation throm-belastography.
J. Thromb. Haemost. 5, 289–95
Schmitt, J. (2010)
Pharmakokinetik von unfraktioniertem und niedermolekularem Heparin bei Katzen und Wirkung auf aktivierte partielle Thromboplastinzeit, Thrombinzeit und
Resonanzthrombogramm.
Inaugural-Dissertation TiHo Hannover WS 2010
Shapiro, G. A., S. W. Huntzinger, J. E. Wilson (1977)
Variation among commercial activated partial thromboplastin time reagents in re-sponse to heparin.
Am. J. Clin. Pathol. 67, 477–488
Shinoda, T., H. Arakura, M. Katakura, T. Shirota, S. Nakagawa (1990)
Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis.
Artif. Organs 14, 413–415
Sinnott, V. B. u. C. M. Otto (2009)
Use of thromboelastography in dogs with immune-mediated hemolytic anemia:
39 cases (2000–2008).
J. Vet. Emerg. Crit. Care 19, 484–488
Sisson, D. D. u. W. P. Thomas (1995)
in: S. J. Ettinger u. E. C. Feldman (Hersg.): Textbook of Veterinary internal medicine.
4. Auflage, Verlag Saunders, Philadelphia, S. 1995
Smith, C. E., E. A. Rozanski, L. M. Freeman, D. J. Brown, J. S. Goodman, J. E.
Rush (2004)
Use of low molecular weight heparin in cats: 57 cases (1999–2003) JAVMA 225, 1237–1241
Smith, S. A., A. H. Tobias, K. A. Jacob, D. M. Fine, P. L. Grumbles (2003)
Arterial thromboembolism in cats: acute crisis in 127 cases (1992–2001) and long-term management with low-dose aspirin in 24 cases.
J. Vet. Inter. Med. 17, 73–83
Smith, S. A., D. C. Lewis, D. L. Kellerman (1998)
Adjustment of intermittent subcutanelous heparin therapy based on chromogenic heparin assay in 9 cats with thromboembolism.
J. Vet. Intern. Med. 12, 200 (Abstract)
Spiess, B. D., B. S. Gillies, W. Chandler, E. Verrier (1995)
Changes in transfusion therapy and reeploration rate after institution of a blood management program in cardiac surgical patients.
J. Cardiothorac. Vasc. Anesth. 9, 168–173
Spieza, L., D. Bertini, M. Boldrin, C. Radu, C. Bulato, S. Gavasso, E. Cozzi, P.
Simioni (2010)
Reference values for thromboelastometry (ROTEM®) in cynomolgus monkeys (Macaca fascicularis).
Thromb. Res. 126, e294–e297
Stahl, R. L., A. Duncan, M. A. Hooks, J. M. Henderson, W. J. Millikan, W. D.
Warren (1990)
A hypercoagulable state follows orthotopic liver transplantation.
Hepatology 12, 553–558
Stokol, T., M. Brooks, J. E. Rush, M. Rishniw, H. Erb, E. Rozanski, M. S. Kraus, A. L. Gelzer (2008)
Hypercoagulability in cats with cardiomyopathy.
J. Vet. Intern. Med. 22, 546–552
Sucker, C., K. Tharra, J. Litmathe, R. E. Scharf R. B. Zotz (2011)
Rotation thromboelastography (ROTEM) parameters are influenced by age, gender and oral contraception.
Perfusion 26, 334–340
Theusinger, O. M., J. Nürnberg, L. M. Asmis, B. Seifert, D. R. Spahn (2010) Rotation thromboelastometry (ROTEM®) stability and reproducibility over time.
Eur. J. Cardiothorac. Surg. 37, 677–683
Thorevska, N., Y. Amoateng-Adjepong, R. Sabahi, I. Schiopescu, A. Salloum, V.
Muralidharan, C. A. Manthous (2003)
Anticoagulation in hospitalized patients with renal insufficiency. A comparison of bleeding rates with unfractionated heparin vs Enoxaparin.
Chest 125, 856–863
van den Besselar, A. M., A. Sturk, G. L. Reijnierse (2002)
Montoring of unfractionated heparin with the activated partial tromboplastin time:
detremination of therapeutic ranges.
Thromb. Res. 107, 235–240
Vandiver, J. W. u. T. G. Vondracek (2012)
Antifactor Xa levels versus activated partial thromboplastin time for monitoring un-fractionated heparin.
Pharmacotherapy 32, 546–558
Velik-Salchner, C., C. Schnürer, D. Fries, P. R. Müssigang, P. L. Moser, W.
Streif, C. Kolbitsch, I. H. Lorenz (2006)
Normal values for thrombelastography (ROTEM®) and selected coagulation parame-ters in porcine blood.
Thromb. Res. 117, 597–602
Vilar, P., C. G. Couto, N. Westendorf, C. Iazbik, J. Charsske, L. Marín (2008) Thromboelastographic tracings in retired racing greyhounds and in non-greyhound dogs.
J. Vet. Intern. Med. 22, 374–379
Volles, D. F., C. J. Ancell, K. A. Michael, D. M. Mullins, J. E. Humphries (1998) Establishing an institution-specific therapeutic range for heparin.
Am. J. Health Syst. Pharm 55, 2002–2006
Wagg, C. R., S. R. Boysen, C. Bédard (2009)
Thrombelastography in dogs admitted to an intensive care unit.
Vet. Clin. Pathol. 38, 453–461
White, H., K. Sosnowski, R. Bird, M. Jones, C. Solano (2012)
The utility of thromboelastography in monitoring low molecular weight heparin thera-py in the coronary care unit.
Blood Coagul. Fibrinolysis 24, 304–310
Wiinberg, B., A. L. Jensen, P. I. Johansson, E. Rozanski, M. Tranholm, A. T.
Kristensen (2008)
Thromboelastographic evaluation of hemostatic function in dogs with disseminated intravascular coagulation.
J. Vet. Inter. Med. 22, 357–365
Wiinberg, B., A. Lundorff-Jensen, E. Rozanski, P. I. Johansson, M. Kjelgard-Hansen, M. Tranholm, A. T. Kristensen (2009)
Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs.
Vet. J. 179, 121–129
Wiinberg, B., A. Lundorff-Jensen, R. Rojkjaer, P. Johansson, M. Kjelgard-Hansen, A. T. Kristensen (2005)
Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs.
Vet. Clin. Pathol. 34, 389–393
Wilson, J. R. u. J. Lampman (1979)
Heparin therapy: a randomized prospective study.
Am. Heart J. 97, 155–158
Zmuda, K., D. Neofotistos, C. Ts´ao (2000)
Effects of unfractionated heparin, low-molecular-weight heparin, and haparinoid on thromboelastographic assay of blood coagulation.
Am. J. Clin. Pathol. 113, 725–731